Home > Boards > Free Zone > All Trading - Technical > THE TRADING DOJO

Silicon Valley biotech trading at .0065 and heading

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Hot Stock Alert Member Profile
Member Level 
Followed By 514
Posts 37,223
Boards Moderated 6
Alias Born 04/26/12
160x600 placeholder
Hot Stock Alert Member Level  Sunday, 01/15/17 08:59:30 AM
Re: None
Post # of 3021 
Silicon Valley biotech trading at .0065 and heading up, ARYC, updates:

Arrayit Silicon Valley store sales exceed $54 million all-time on 222,269 microarray products and services
http://
shop.arrayit.com

Arrayit receives new financing lead that could generate 6,000 x $100K = $600MM in Arrayit microarray platform sales
http://
arrayit.com

Arrayit signs 3-year $24.4 million patented microarray technology sales and marketing agreement with a leading laboratory services provider.

Arrayit Corporation ?@arrayit
Arrayit quotes $16,000,000 microarray services contract to top US-based research laboratory http://arrayit.com/Services/services.html

Arrayit backorders soar to record $2.5MM on strong demand for microarray products & services
http://
arrayit.com/index.html

Arrayit Corporation

http://www.arrayit.com/

Check out their Facebook page: Arrayit Corporation

Follow $ARYC on Twitter @Arrayit

Avant Diagnostics, Inc. provide the market’s first large panel biomarker monitoring test for ovarian cancer (OVC). OvaDx® is advanced microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA approval, Avant will offer OvaDx® as an elective test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. OvaDx® will be used by doctors to advance the forefront of ovarian cancer treatment including improved surgical options, more effective chemotherapies, and to supplement existing tests including CA-125, OVA1®, and transvaginal ultrasound.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist